RBC Capital analyst Kennen MacKay keeps his Outperform rating on Alexion after the company's surprise announcement that its CFO Paul Clancy is stepping down. The analyst notes that his follow-up discussions with the management suggest that the departure of Mr. Clancy was not related to an alternative role in the industry but rather his plans to pursue non-operational roles. MacKay adds that Alexion intends to maintain its focus on execution, including the conversion of Soliris-treated patients to next-generation Ultomiris, and sees the incoming CFO Aradhana Sarin as a "strong successor" given her prior role as a SVP in Business Development.